MYB and neoplasm: The latter are considered novel, not yet published (provisional) molecular subclasses according to MNP12.5.7 There were 3 additional tumors (7.5%) of the pediatric-type DHG_G34, and individual cases (n = 1, 2.5% each) representing the midline DMG_EGFR subclass, or MYB(L1)-altered diffuse glioma, subtype D. Notably, there was only 1 tumor of the pedHGG_RTK1A/B/C subclass of a child, who had received previous CNS irradiation for leukemia.